Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Ugo Boggi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7505-5896; OpenAlex author ID A5008369490, A5015189613, A5049957859, A5088139413. Sources: ClinicalTrials.gov.

Their work

Papers
73 (first author 2, last author 8)
Trials
1
Grants
0
Labs led
1
Collaborators
244
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: 5 papers · 2015: none · 2016: 3 papers · 2017: 3 papers · 2018: 4 papers · 2019: 4 papers · 2020: 4 papers, 1 trial · 2021: 11 papers · 2022: 4 papers · 2023: 10 papers · 2024: 7 papers · 2025: 4 papers · 2026: 9 papers

Papers 50 of 73

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Pancreatic ductal adenocarcinoma and pancreatic surgery in the 21st century: triumphs, turning points, and unresolved challenges. Last author DOI 10.1007/s13304-025-02502-9↗
  3. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Last author DOI 10.1007/s13304-026-02598-7↗
  4. Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future. Co-author DOI 10.1007/s13304-026-02651-5↗
  5. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  6. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  7. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  8. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  9. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  10. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  11. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  12. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  13. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  14. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  15. Minimally invasive versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma: an entropy balancing analysis. Co-author DOI 10.1016/j.hpb.2023.09.013↗
  16. Rediscover: An Italian and international consensus meeting on locally advanced pancreatic cancer. First author DOI 10.1016/j.sopen.2023.11.001↗
  17. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  18. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  19. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  20. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  21. Multi-visceral resection for left-sided pancreatic ductal adenocarcinoma: a multicenter retrospective analysis from European countries. Co-author DOI 10.1007/s00423-023-03110-0↗
  22. Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas. Last author DOI 10.1007/s13304-023-01587-4↗
  23. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  24. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  25. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment. Co-author DOI 10.1016/j.ejso.2022.12.006↗
  26. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  27. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  28. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  29. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  30. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  31. 2021 SSAT Debate: Selective Approach to Resection of the Superior Mesenteric Artery in Pancreatic Cancer vs Superior Mesenteric Artery Encasement Is Not an Abs… Co-author DOI 10.1007/s11605-021-05237-1↗
  32. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  33. The importance of vascular anatomy and r1 site in the oncologic outcome of pancreatoduodenectomy for pancreatic cancer: The case of an aberrant right hepatic a… Co-author DOI 10.1016/j.surg.2022.04.009↗
  34. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  35. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  36. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. Last author DOI 10.1007/s13304-020-00883-7↗
  37. Resection for pancreatic cancer with arterial involvement: A paradigm shift away from unresectable to "how to do it". Co-author DOI 10.1016/j.surg.2020.10.047↗
  38. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… Co-author DOI 10.1097/as9.0000000000000087↗
  39. Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Pr… Co-author DOI 10.1097/sla.0000000000003717↗
  40. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  41. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  42. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  43. Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08658-5↗
  44. The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospecti… Co-author DOI 10.1245/s10434-020-09310-y↗
  45. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  46. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  47. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  48. Impact of nutritional status on outcome of pancreatic resections for pancreatic cancer and periampullary tumors. Last author DOI 10.21037/hbsn-20-498↗
  49. Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. Co-author DOI 10.3389/fonc.2020.00064↗
  50. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗

Trials 1

  1. Evaluation of Difficulty Score for Robotic Pancreatoduodenectomy Study chair NCT04662346↗

Closest collaborators

The 25 strongest of 244 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Emanuele F. Kauffmann · 10 shared papers, 2019–2026 · strength 1.58
  2. Niccolò Napoli · 12 shared papers, 2016–2026 · strength 1.43
  3. Marc G. Besselink · 12 shared papers, 2018–2026 · strength 1.41
  4. Alessandro Zerbi · 9 shared papers, 2020–2026 · strength 1.29
  5. Riccardo Casadei · 8 shared papers, 2020–2026 · strength 1.11
  6. Massimo Falconi · 9 shared papers, 2020–2024 · strength 1.04
  7. Enrico Vasile · 10 shared papers, 2011–2026 · strength 0.90
  8. Roberto Salvia · 8 shared papers, 2018–2026 · strength 0.87
  9. Sergio Alfieri · 4 shared papers, 2024–2026 · strength 0.82
  10. Daniela Campani · 11 shared papers, 2011–2023 · strength 0.76
  11. Mohammad Abu Hilal · 7 shared papers, 2020–2024 · strength 0.73
  12. Nicholas Joseph Zyromski · 2 shared papers, 2022–2024 · strength 0.72
  13. Thilo Hackert · 6 shared papers, 2018–2026 · strength 0.70
  14. Allegra Ripolli · 3 shared papers, 2025–2026 · strength 0.70
  15. Jony van Hilst · 7 shared papers, 2018–2024 · strength 0.62
  16. Giuseppe Fusai · 5 shared papers, 2018–2026 · strength 0.62
  17. Safi Dokmak · 5 shared papers, 2020–2024 · strength 0.53
  18. Giovanni Butturini · 5 shared papers, 2020–2024 · strength 0.53
  19. Tobias Keck · 5 shared papers, 2020–2024 · strength 0.52
  20. Maarten Korrel · 5 shared papers, 2020–2024 · strength 0.52
  21. Bas Groot Koerkamp · 4 shared papers, 2021–2026 · strength 0.51
  22. Bjørn Edwin · 5 shared papers, 2020–2023 · strength 0.50
  23. Sanne Lof · 5 shared papers, 2020–2023 · strength 0.50
  24. Andrea Pietrabissa · 4 shared papers, 2021–2024 · strength 0.48
  25. Claudio Bassi · 6 shared papers, 2013–2022 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.